{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT01633723: Phase 1 Interventional Completed Irritable Bowel Syndrome
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
DA-6886 is an antagonist of the 5-HT4 receptor, discovered by the Korean Dong-A ST Research Institute. The drug binds with high activity and selectivity to human 5-HT4 receptor splice variants, with mean pKi of 7.1, 7.5 and 7.9 for the human 5-HT4a, 5-HT4b, and 5-HT4d, respectively. DA-886 induced relaxation of the rat esophagus preparation in a 5-HT4 receptor antagonist-sensitive manner. In the normal ICR mice, oral administration of the drug at 0.4 and 2 mg/kg resulted in a marked stimulation of colonic transit. DA-6886 was investigated in phase I clinical trial for the treatment of Irritable Bowel Syndrome.
Status:
Investigational
Source:
NCT03964493: Phase 2 Interventional Completed Skin and Subcutaneous Tissue Bacterial Infections
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04279847: Phase 1 Interventional Recruiting Myelofibrosis
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
INN:nedemelteon [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02542787: Phase 2 Interventional Completed Spasticity in People With Multiple Sclerosis
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
INN:zelnecirnon [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03920254: Phase 2/Phase 3 Interventional Terminated Ulcerative Colitis (UC)
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02089061: Phase 1 Interventional Completed Acute Coronary Syndromes
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Bristol-Myers Squibb developed BMS-919373, a selective IKur inhibitor for use in atrial fibrillation, acute coronary syndromes, and paroxysmal atrial fibrillation. IKur is a repolarizing K+ current encoded by the KCNA5 gene and is expressed predominantly in the atrium of human. IKur is a potential atrial-selective target for the treatment of atrial fibrillation. BMS-919373 participated in phase II clinical trials to evaluate the effect on atrial fibrillation burden in patients with paroxysmal atrial fibrillation. In addition, in phase I clinical trials for patients with acute coronary syndromes. However, further, developments have been discontinued.
Status:
Investigational
Source:
NCT02326441: Phase 1 Interventional Completed Advance Malignancies
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
KX-02 is a compound demonstrating dual inhibitory activity against Src kinase and tubulin polymerization. It readily crosses the blood-brain-barrier in mice. It is under development for the treatment of solid tumors.
Status:
Investigational
Source:
NCT03013998: Phase 1/Phase 2 Interventional Recruiting Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
HCI-2084 (wider known as TP-0903) is developing by Tolero Pharmaceuticals for the treatment of different cancers. HCI-2084 is a small molecule AXL receptor tyrosine kinase (RTK) inhibitor. AXL is involved in maintaining a mesenchymal phenotype in cancer cells that enhanced cell survival in stressed environments, and increased resistance to targeted therapies compared to epithelial cells. AXL overexpression has been observed in multiple tumor types that have acquired resistance to various agents. TP-0903 is participating in phase I/II clinical trial in patients with previously treated chronic lymphocytic leukemia (CLL). This study will investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of TP-0903. Besides, phase I is currently being conducted in patients with advanced solid tumors in the presence of TP-0903. In addition, TP-0903 was investigated in neuroblastoma (NB) cells, where this drug makes NB cells more vulnerable to the conventional chemotherapeutics.
